Phase 2 study finds intranasal esketamine effective in treatment‐resistant depression
The Brown University Psychopharmacology Update March 9, 2018 DOI: 10.1002/pu.30309 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Multiphase study Peer reviewed |
|---|---|
| Sample size | 67 |
| Population | Patients with treatment-resistant depression |
| Interventions | Intranasal esketamine antidepressant |
| Topics | Depression Esketamine |
| Key points | Intranasal esketamine as adjunctive therapy with an antidepressant produced greater symptom improvement than adjunctive placebo in patients with treatment-resistant depression, and the antidepressant effect was dose-related. Only a small number of participants discontinued due to adverse events. |
Abstract
Patients with treatment‐resistant depression who received intranasal esketamine as adjunctive therapy with an antidepressant experienced greater symptom improvement than patients receiving adjunctive placebo, a multiphase study with 67 participants has found. The antidepressant effect seen in the study was dose‐related, and adverse events led to study discontinuation in only a small number of participants. Study results were published online Dec. 27, 2017, in JAMA Psychiatry.